Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | -0.10 | 0.01 |
| FCF Yield | -191.16% | -46.65% | -37.37% | -50.29% |
| EV / EBITDA | -0.29 | -0.71 | -2.09 | -1.67 |
| Quality | ||||
| ROIC | 137.52% | 360.70% | 208.68% | -178.66% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 74.04% |
| Cash Conversion Ratio | 1.17 | 0.56 | 0.78 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 81.81% | -86.95% | – | – |
| Free Cash Flow Growth | -22.30% | 27.41% | 4.38% | -28.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.50 | 0.02 | 0.73 |
| Interest Coverage | -1,693.50 | 0.00 | 0.00 | -181.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 354.08 | 1,704.81 | 405.39 | -5,361.89 |